AKT1 and neoplasm: Ricci’s team [19] established some special PDXs of ovarian cancer, such as recurrent tumor and Akt and ERK pathway platinum-resistant tumor, which verified the efficacy of antitumor multi-drug (paclitaxel, bevacizumab, and MEK inhibitor).